Nintedanib Zentiva

Nintedanib, the active ingredient in Nintedanib Zentiva, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease and non‑small cell lung cancer in appropriate patients.

GNH USA supplies Nintedanib Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nintedanib acts on fibrotic and oncogenic pathways to modify disease progression in several lung conditions.

- Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression. - Systemic sclerosis‑associated interstitial lung disease: helps preserve lung capacity and delays worsening. - Non‑small cell lung cancer: used in combination regimens to inhibit tumor growth and angiogenesis.

Nintedanib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Decreased appetite: reduced desire to eat. - Elevated liver enzymes: mild hepatic enzyme rise.

Serious or Rare Side Effects: - Hepatic failure: severe liver injury requiring monitoring. - Arterial thromboembolic events: risk of clot formation. - Severe bleeding: especially when combined with anticoagulants. - Gastrointestinal perforation: rare but serious intestinal injury. - Pneumothorax: collapsed lung in vulnerable patients. - Severe infections: opportunistic infections in immunocompromised individuals.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor key parameters.

- Renal function: assess baseline creatinine and monitor during treatment. - Hepatic function: avoid use in severe liver impairment; check enzymes regularly. - Bleeding risk: use caution with anticoagulants or antiplatelet drugs. - Pregnancy and lactation: avoid use; safety not established. - Drug interactions: review concomitant medications for CYP3A4 modulators. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Nintedanib may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: increase nintedanib exposure and toxicity risk. - Anticoagulants/antiplatelet agents: heighten bleeding potential. - P‑glycoprotein inhibitors: may raise plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers: may reduce therapeutic effectiveness. - Diuretics: can affect renal clearance of the drug. - Antacids: may alter absorption if taken simultaneously; separate dosing recommended.